JPRN-UMIN000003566已完成2 期
Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer - Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital0 个研究点目标入组 33 人开始时间: 2010年5月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
The overall response rate was 76%. The median progression free survival and overall survival were 8.4 months and 22.2 months, respectively. Grade 3-4 toxicities included neutropenia in 55% of patients, anemia in 18%, febrile neutropenia in 12%, and anorexia in 9%. No treatment-related deaths were observed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) brain metastasis (2) active concomitant malignancy (3) Current or previous history of hemoptysis or active hemosputum (4) evidence of bleeding diathesis or coagulopathy (5) Current or previous history of Pericardial effusion (6) superior vena cava syndrome (7) spinal cord compression (8) Current or previous (within the last 1 year) history of cerebrovascular disease (9) Traumatic fracture of unrecovery (10) History of active infection (11) The operation has been scheduled for the examination period (12) receiving anticoagulant drug(except Aspirin under 324mg/day) (13) Uncontrollable Gastrointestinal ulceration (14) Current or previous (within the last 1 year) history of GI perforation (15) Uncontrollable hypertension (16) severe cardiac disease (17)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan or X-ray (18)peripheral neuropathy > Grade2 (19) severe drug allergy (20) history of hypersensitivity of Taxans or alcohol and the medicine made of the polio castor oil content (21) treatment history of bevacizumab (22) History of pregnancy or lactation (23) No intention to practice birth control (24) those judged to be not suitable by the attending physician
研究者
相似试验
已完成
2 期
JGOG1079Stage IVB, recurrent or persistant cervical cancerJPRN-jRCTs051180157TAKESHIMA Nobuhiro73
已完成
2 期
A phase II Study of Bevacizumab plus oral S1 previously treated non-small cell lung Cancer (OSAKA-LCSG1202)Previously treated non-small cell lung cancerJPRN-UMIN000008158Dept. of Respiratory Medicine, Osaka University Hospital30
已完成
2 期
A phase II study of maintenance bevacizumab plus docetaxel following induction chemotherapy with cisplatin, pemetrexed plus bevacizumab for advanced non-squamous non-small-cell lung cancerAdvanced non-squamous non-small cell lung cancerJPRN-UMIN000014314Hamamatsu Univ. School of Medicine49
已完成
2 期
Weekly nab-PTX in Combination with Gemcitabine in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapyon-Small-Cell Lung CancerJPRN-UMIN000017010Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine28
已完成
2 期
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By SurgeryHepatocellular CarcinomaLiver CancerNCT00242502M.D. Anderson Cancer Center62